Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $989.71M | $766.21M | $874.57M | $776.13M | $825.41M | $745.15M | $747.31M | $745.74M |
| Cost of revenue | $202.80M | $195.00M | $275.71M | $140.09M | $150.09M | $151.56M | $136.14M | $188.46M |
| Gross profit | $786.91M | $571.21M | $598.86M | $636.05M | $675.32M | $593.59M | $611.17M | $557.28M |
| Gross margin | 79.5% | 74.6% | 68.5% | 82.0% | 81.8% | 79.7% | 81.8% | 74.7% |
| Research and development | $206.95M | $178.80M | $192.41M | $409.48M | $161.31M | $158.73M | $173.51M | $184.90M |
| Selling, general and administrative | $395.55M | $258.29M | $446.21M | $268.42M | $232.28M | $206.12M | $266.61M | $253.48M |
| Operating expenses | $672.71M | $441.57M | $643.47M | $682.74M | $393.60M | $369.69M | $449.77M | $443.39M |
| Operating income | $114.20M | $129.64M | −$44.61M | −$46.69M | $281.72M | $223.89M | $161.41M | $113.89M |
| Operating margin | 11.5% | 16.9% | -5.1% | -6.0% | 34.1% | 30.0% | 21.6% | 15.3% |
| EBITDA | $211.84M | $146.05M | −$24.17M | −$28.21M | $300.28M | $245.96M | $185.01M | $132.90M |
| Interest income | $10.48M | $22.56M | $19.21M | $17.85M | $18.83M | $19.01M | $17.68M | $18.05M |
| Interest expense | −$63.30M | −$14.96M | −$2.78M | −$2.58M | −$2.68M | −$2.86M | −$2.58M | −$2.97M |
| Income before taxes | $61.38M | $141.20M | −$27.15M | −$26.32M | $297.87M | $238.09M | $169.64M | $134.44M |
| Income taxes | $16.62M | $35.68M | $19.42M | $4.42M | $57.34M | $52.40M | $44.70M | $28.36M |
| Net income | $44.76M | $105.53M | −$46.57M | −$30.74M | $240.53M | $185.69M | $124.94M | $106.08M |
| Net margin | 4.5% | 13.8% | -5.3% | -4.0% | 29.1% | 24.9% | 16.7% | 14.2% |
| EPS, basic | $0.23 | $0.55 | −$0.24 | −$0.16 | $1.25 | $0.97 | $0.66 | $0.56 |
| EPS, diluted | $0.23 | $0.54 | −$0.23 | −$0.16 | $1.23 | $0.95 | $0.66 | $0.55 |
| Diluted shares | 194.47M | 197.67M | 203.98M | 192.03M | 197.09M | 196.47M | 189.92M | 197.15M |
Figures describe BioMarin Pharmaceutical shares, not any token. As of Aug 6, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.